Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSarah BertoliEBEmilie BérardLLLaëtitia Largeaud

Discussion

Loading...

Member takes

Overview

Multicentric analysis shows improved survival rates in acute myeloid leukemia with tyrosine kinase inhibitors, indicating a potential standard of care.

Key Points

  • Treatment with tyrosine kinase inhibitors led to significant enhancements in patient outcomes for acute myeloid leukemia.
  • In the analysis, the overall survival rate reached 70.9% compared to 42.1% with intensive chemotherapy alone.
  • Multicentric retrospective data collection across Europe revealed notable improvements in response rates with the addition of kinase inhibitors.
  • These findings support revising the classification of de novo BCR::ABL1+ acute myeloid leukemia from adverse to a more favorable risk level.

Cite This Study

Bertoli et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e376https://doi.org/10.1182/blood-2025-991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase2025
  2. 2Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia2025
  3. 3Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor2025
  4. 4Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia2025
  5. 5Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium2025 · 1 citations